Bakri balloon
The Bakri balloon is a medical device invented and designed by Dr. Younes Bakri in 1999.[1]
The obstetrical balloon is a 24 French, 54 cm-long, silicone catheter with a filling capacity of 500 mL. The device is used for the temporary control and reduction of postpartum hemorrhage (PPH).
According to the World Health Organization, around 100,000 maternal deaths occur every year from PPH and is the leading cause of maternal mortality in the developed world.[2]
Use
[edit]The Bakri balloon is a silicone, obstetrical balloon specifically designed to treat postpartum hemorrhage (PPH). The device is used for the "temporary control or reduction of postpartum hemorrhage when conservative management of uterine bleeding is warranted."[1]
Cases
[edit]One study in Finland[3] involving 50 patients recorded an overall success rate of 86% when using the Bakri balloon in managing PPH. A German study involving 20 patients cited an overall success rate of 90% when the balloon is used in combination with B-Lynch sutures.[4]
In 2023, a 4-year case study (2016–2020) in China involving 279 women was published and concluded that the Bakri balloon was an effective treatment in controlling postpartum hemorrhage. The overall success rate was 88.89% and supported those from previous studies. [5]
Endorsements
[edit]Both the International Federation of Gynaecology and Obstetrics (FIGO) and the International Confederation of Midwives (ICM) have approved the balloon as one of the primary support tools in treating PPH.[6]
In 2021, the World Health Organization recommended the Bakri Balloon as part of its guidelines to help reduce the maternal mortality ratio to less than 70 per 100,000 live births by 2030.[7]
See also
[edit]References
[edit]- ^ a b "Bakri® Postpartum Balloon with Rapid Instillation Components". Cook Medical Products.
- ^ Abouzahr, C (1998). "Antepartum and postpartum haemorrhage". In Murray, Christopher J. L.; Lopez, Alan D. (eds.). Health Dimensions of Sex and Reproduction: The Global Burden of Sexually Transmitted Diseases, HIV, Maternal Conditions, Perinatal Disorders, and Congenital Anomalies. Harvard School of Public Health. pp. 172–174. ISBN 978-0-674-38335-7.
- ^ Grönvall, Maiju; Tikkanen, Minna; Tallberg, Erika; Paavonen, Jorma; Stefanovic, Vedran (2013). "Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: A series of 50 cases from a tertiary teaching hospital". Acta Obstetricia et Gynecologica Scandinavica. 92 (4): 433–438. doi:10.1111/j.1600-0412.2012.01531.x. PMID 22913383. S2CID 2851504.
- ^ Diemert, Anke; Ortmeyer, Gerhard; Hollwitz, Bettina; Lotz, Manuela; Somville, Thierry; Glosemeyer, Peter; Diehl, Werner; Hecher, Kurt (2012). "The combination of intrauterine balloon tamponade and the B-Lynch procedure for the treatment of severe postpartum hemorrhage". American Journal of Obstetrics and Gynecology. 206 (1): 65.e1–65.e4. doi:10.1016/j.ajog.2011.07.041. PMID 22000893.
- ^ Xiao, C.; Wang, Y.; Zhang, N.; Sun, G. Q. (2023). "Bakri Balloon for Treatment of Postpartum Hemorrhage: A Real-World 2016–2020 Study in 279 Women from a Single Center". Medical Science Monitor. 29: e938823-1-e938823-9. doi:10.12659/MSM.938823. PMC 9987168. PMID 36855288.
- ^ Lalonde, André (May 2012). "Prevention and treatment of postpartum hemorrhage in low-resource settings". International Journal of Gynecology & Obstetrics. 117 (2): 108–118. doi:10.1016/j.ijgo.2012.03.001. PMID 22502595. S2CID 34206676.
- ^ WHO recommendation on uterine balloon tamponade for the treatment of postpartum haemorrhage. World Health Organization. 2021. hdl:10665/340796. ISBN 978-92-4-001384-1.[page needed]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.